| An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer C To, TS Beyett, J Jang, WW Feng, M Bahcall, HM Haikala, BH Shin, ... Nature cancer 3 (4), 402-417, 2022 | 71 | 2022 |
| Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors TS Beyett, C To, DE Heppner, JK Rana, AM Schmoker, J Jang, ... Nature communications 13 (1), 2530, 2022 | 39 | 2022 |
| Design of a “two-in-one” mutant-selective epidermal growth factor receptor inhibitor that spans the orthosteric and allosteric sites F Wittlinger, DE Heppner, C To, M Günther, BH Shin, JK Rana, ... Journal of medicinal chemistry 65 (2), 1370-1383, 2021 | 18 | 2021 |
| Macrocyclization of quinazoline-based EGFR inhibitors leads to exclusive mutant selectivity for EGFR L858R and Del19 JA Amrhein, TS Beyett, WW Feng, A Krämer, J Weckesser, IK Schaeffner, ... Journal of medicinal chemistry 65 (23), 15679-15697, 2022 | 8 | 2022 |
| Allosteric inhibition of drug resistant forms of EGFR L858R mutant NSCLC C To, TS Beyett, J Jang, WW Feng, M Bahcall, HM Haikala, BH Shin, ... Nature cancer 3 (4), 402, 2022 | 4 | 2022 |
| Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor F Wittlinger, DE Heppner, C To, M Guenther, BH Shin, JK Rana, ... | 2 | 2020 |
| Structural analysis of the macrocyclic inhibitor BI-4020 binding to EGFR kinase TS Beyett, JK Rana, IK Schaeffner, DE Heppner, MJ Eck bioRxiv, 2022.08. 27.505540, 2022 | 1 | 2022 |
| Structure of the human systemic RNAi defective transmembrane protein 1 (hSIDT1) reveals the conformational flexibility of its lipid binding domain V Navratna, A Kumar, JK Rana, S Mosalaganti bioRxiv, 2023.12. 21.572875, 2023 | | 2023 |
